ESG

With two key acquisitions, Currier Plastics expands its footprint and cleanroom capacity, signaling a major consolidation play by Sheridan Capital Partners.

With a new EV plant in Santa Teresa, GreenPower aims for market dominance while New Mexico pushes its ambitious clean energy and economic development goals.

The investment giant's new podcast season tackles the energy trilemma, exploring AI's power thirst, the return of nuclear, and fossil fuel's role.

BEGA's new BEGA Connect platform leverages cloud power and NB-IoT to simplify architectural lighting control, eliminating servers and subscription fees.

A new study on oral testosterone therapy for men 65-80 could reshape geriatric care, challenge FDA guidelines, and unlock a multi-billion dollar market.

The LA Rams and energy firm CRC mark one year of a partnership to offset team emissions, but does this innovative, local-first model truly change the game?

With pivotal data for its sickle cell drug and a new myelofibrosis program, Cellarity's AI-driven 'Cell State-Correcting' platform faces a crucial test.

Safi Biotherapeutics and ARMI | BioFabUSA achieve a critical step toward mass-producing red blood cells, offering hope for patients and military readiness.

The biotech firm launches an early access program for its novel platform, starting with a tau assay that could revolutionize Alzheimer's research.

With a major cash infusion and key pipeline milestones, Xilio Therapeutics validates its tumor-activated approach to fighting cancer and extends its runway to 2027.

Positive early human safety data for its lead drug and new candidates for Rett syndrome and MASH signal a pivotal year for ProQR's Axiomer technology.

Sunwoda deepens its Sungrow alliance, unveiling advanced battery tech and a robust ESG strategy to lead the global clean energy transition.

Klotho Neurosciences will present its novel gene therapy for Alzheimer's and ALS at a key summit, seeking to turn scientific promise into clinical reality.

A new partnership aims to bring cutting-edge cancer trials to community clinics, accelerating drug development and expanding patient access to care.

With a potential winter drill program at its Tharsis REE project and high-grade results at Big Mack, the company is advancing two key Canadian assets.

With record growth and a fortified cash position, ElevateBio combines AI-driven discovery and industrial-scale manufacturing to power the gene therapy boom.

With a key FDA meeting set, Trevi Therapeutics pushes its drug Haduvio into late-stage trials, offering hope for millions with no approved treatments.

A new vectorized antibody therapy for ALS, VTx-002, has been granted FDA Fast Track status, accelerating its path to patients battling the disease.

The medtech firm's preliminary results show a Q4 revenue uptick but miss yearly estimates, signaling a stabilizing but cautious path forward for 2026.

Otis secures a major TfL contract to upgrade 172 escalators, blending a century of history with future-ready tech for a smarter, more reliable commute.